Cartherics and Catalent Extend Scope of Existing Commercial Licensing Agreement
Cartherics Pty Ltd, a clinical-stage biotechnology company focused on developing next-generation immune cell therapies for high-impact women’s health conditions, has announced an expanded strategic partnership with Catalent, Inc., a global leader in enabling the development and supply of advanced therapeutics. The enhanced collaboration centers on an amended commercial license agreement that grants Cartherics access to a cGMP-compliant induced pluripotent stem cell (iPSC) line developed by Catalent, supporting the manufacture and commercialization of Cartherics’ pipeline of iPSC-derived chimeric antigen receptor natural killer (CAR-NK) cell therapies.
This development marks a significant milestone for Cartherics as it advances its mission to deliver scalable, off-the-shelf immune cell therapies targeting diseases that disproportionately affect women, including ovarian cancer and endometriosis. By leveraging Catalent’s established expertise in cell therapy manufacturing and its portfolio of clinical-grade iPSC lines, Cartherics aims to accelerate the development timeline of its innovative therapeutic candidates while ensuring high standards of quality, consistency, and regulatory compliance.
At the core of the agreement is the use of Catalent’s current Good Manufacturing Practice (cGMP)-compliant iPSC line, which serves as a foundational starting material for the generation of CAR-NK cell therapies. Induced pluripotent stem cells are a transformative platform in regenerative medicine and cell therapy, as they can be reprogrammed from adult cells into a pluripotent state and subsequently differentiated into a wide variety of specialized cell types. In this case, the iPSC line is engineered and expanded to produce natural killer (NK) cells that are further modified with chimeric antigen receptors (CARs), enabling them to recognize and target cancer cells with enhanced specificity and potency.
Unlike autologous cell therapies, which are derived from a patient’s own cells and often involve complex, time-consuming manufacturing processes, iPSC-derived CAR-NK therapies offer the potential for an allogeneic, off-the-shelf approach. This means that therapies can be manufactured in advance, stored, and made readily available to patients when needed, significantly reducing treatment delays and improving accessibility. Additionally, NK cells are known for their favorable safety profile compared to other immune cell types, making them an attractive platform for next-generation cancer immunotherapies.
Dr. Ian Nisbet, Chief Executive Officer of Cartherics, highlighted the importance of the collaboration in driving forward the company’s development strategy. He expressed enthusiasm about strengthening ties with Catalent, noting that the partnership provides a strong foundation for accelerating the clinical and commercial progress of Cartherics’ CAR-NK programs. He also emphasized that Catalent’s capabilities as a leading contract development and manufacturing organization (CDMO) will play a critical role in enabling cost-effective and scalable production of these advanced therapies.
Echoing this sentiment, David McErlane, President of Catalent’s Biologics division, underscored the strategic value of the expanded agreement. He noted that Catalent is committed to supporting Cartherics’ efforts to develop innovative NK cell-based treatments for cancer and other serious conditions. According to McErlane, the collaboration reflects a shared dedication to advancing cutting-edge therapies through all stages of development, from early research to commercialization, with the ultimate goal of improving patient outcomes worldwide.
Under the terms of the amended license agreement, Cartherics is granted rights to develop and commercialize multiple therapeutic candidates derived from Catalent’s iPSC platform. This includes the company’s lead program, CTH-401, a CAR-NK cell therapy designed to target specific tumor-associated antigens. The licensed iPSC line is part of Catalent’s broader portfolio of well-characterized, donor-consented, and clinical-grade cell lines, all produced under stringent GMP conditions. These cell lines are supported by validated and scalable workflows that encompass key processes such as cellular reprogramming, expansion, gene editing, differentiation into NK cells, and rigorous quality control testing.
Importantly, the collaboration has already achieved a notable regulatory milestone. With Catalent’s support, Cartherics has secured clearance from the U.S. Food and Drug Administration to use the licensed iPSC line as the starting material for generating CTH-401. This regulatory endorsement not only validates the quality and suitability of the iPSC line but also provides a clear pathway for advancing the program into clinical development. In addition, the two companies have demonstrated full compatibility between CTH-401 and Catalent’s proprietary iPSC-NK manufacturing platform, further de-risking the development process and supporting seamless scale-up.
The agreement also strengthens Cartherics’ manufacturing strategy by establishing a collaborative framework that incentivizes the use of Catalent as its CDMO partner for late-stage clinical trials and eventual commercial supply. Catalent’s global manufacturing network and deep expertise in biologics production are expected to provide Cartherics with the infrastructure and technical capabilities needed to meet growing demand as its therapies progress through the clinical pipeline.
At the same time, the partnership preserves Cartherics’ operational flexibility. The company retains the ability to manufacture clinical trial materials independently and maintains the option to participate in downstream manufacturing activities as the collaboration evolves. This hybrid approach allows Cartherics to balance the benefits of external manufacturing support with the development of its own internal capabilities, positioning the company for long-term growth and sustainability.
Beyond the immediate scope of the agreement, both Cartherics and Catalent view this collaboration as a critical step toward realizing the broader potential of iPSC-derived cell therapies. The ability to produce standardized, high-quality immune cells at scale has far-reaching implications for the treatment of cancer and other complex diseases. In particular, Cartherics’ focus on conditions such as ovarian cancer and endometriosis addresses significant unmet medical needs, as these diseases often lack effective treatment options and disproportionately impact women’s health globally.
The expanded partnership also reflects broader trends in the biopharmaceutical industry, where collaborations between innovative biotech companies and established CDMOs are becoming increasingly important. Such partnerships enable smaller, research-driven organizations to leverage the infrastructure, expertise, and regulatory experience of larger manufacturing partners, thereby accelerating the translation of scientific discoveries into clinically viable therapies.
In conclusion, the enhanced agreement between Cartherics and Catalent represents a strategic and mutually beneficial collaboration aimed at advancing the development and commercialization of next-generation CAR-NK cell therapies. By combining Cartherics’ innovative science with Catalent’s manufacturing excellence, the partnership is well-positioned to deliver scalable, cost-effective, and accessible treatments for patients with cancer and other serious diseases. As both companies continue to work closely together, their shared commitment to innovation and patient-centric solutions is expected to drive meaningful progress in the rapidly evolving field of cell and gene therapy.
About Catalent
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) championing missions that help people live better and healthier lives. Every product that Catalent helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. Catalent provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives.
Catalent tailors end-to-end solutions to meet customers’ needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at nearly 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually.
For more information, visit www.catalent.com.
About Cartherics
Cartherics Pty Ltd is a privately held biotechnology company based in Melbourne, Australia developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis. The Company’s allogeneic (“off-the-shelf”) cell platform is based upon induced pluripotent stem cells (iPSCs) generated from donated cord blood that can be differentiated into NK cells, T cells and other cells of the immune system. The iPSCs are genetically engineered at specific “safe harbour” genomic sites to provide enhanced function for the derived NK and other immune cells.
The Company’s lead product, CTH-401, is a CAR-iNK cell product. It carries a CAR directed against TAG-72, a well-validated tumour target, along with the deletion of two genes associated with immunosuppression. The company has a strong pipeline of additional novel CAR-immune cell products tailored to disrupt a variety of cancers including; ovarian, triple negative breast cancer and other solid tumours; and is also targeting severe endometriosis with specific NK cell products.
Source Link:https://www.businesswire.com/
